ParaMedir, an innovative medical technology company based in the Northern Netherlands, is proud to announce the significant EFRO subsidy of about €600,000.00 awarded by SNN (Samenwerkingsverband Noord-Nederland). This subsidy will support a groundbreaking consortium led by ParaMedir in their mission to improve healthcare through innovative (bio)monitoring solutions. Next to the subsidy granted by the SNN, the province of Groningen and the municipality of Groningen have both agreed to finance this project as well, contributing about €130,000.00, underlining the importance of this project for the region.
The consortium, consisting of valued partners including the University Medical Centre Groningen (UMCG), Health Hub Roden, and GitGud Software Development, aims to address the urgent challenge of diagnosing and monitoring patients with acute heart failure. Acute heart failure affects 25 million patients globally, with rising incidence and high hospitalization rates. The readmission rate is alarming, and the mortality rate is significant. The standard treatment approach involves restoring the patient's fluid balance using diuretics to eliminate salt and fluid from the patient's body. Currently, treatment of acute heart failure relies on frequent urine collections analyzed through conventional methods.
Cardiodrop©, a groundbreaking innovation, will enable rapid and frequent bedside urine analysis. Building on ParaMedir’s proprietary technology, CardioDrop© will be optimized for use in acute heart failure patients. It facilitates personalized treatment in cardiac care units (CCUs) and intensive care units (ICUs) by monitoring biomarkers and electrolytes. Cardiodrop's implementation in CCUs and ICUs will significantly enhance the quality of life for acute heart failure patients and their caregivers. It will reduce mortality rates, readmissions, and healthcare costs. Additionally, it enables early detection and treatment of renal failure, revolutionizing care provision and improving well-being.
The EFRO subsidy awarded by SNN in the Northern Netherlands is a proof of the consortium's dedication to advancing medical technology and improving patient care. ParaMedir extends its gratitude to SNN and the consortium partners for their commitment and collaborative efforts.
ParaMedir is an innovative medical technology company based in the North of the Netherlands. By developing innovative (bio)monitoring solutions that seamlessly integrate into patient care, ParaMedir aims to revolutionize the healthcare industry. Through the fusion of two promising technologies - biosensing and microfluidics - Paramedir has developed a robust platform that enables real-time continuous monitoring of crucial biomarkers. The first product in development is UriMoni™, a diagnostic device developed for bedside monitoring and prediction of Acute Kidney Injury (AKI).
UriMoni™ and CardioDrop© comprises an array of micro(bio)sensors that monitor relevant biomarkers. These electrochemical micro(bio)sensors, assembled based on extensive ParaMedir intellectual property, provide selective and sensitive measurements of key urinary biomarkers. Proprietary algorithms convert the electrochemical output into biochemical and clinically relevant information, enabling doctors to assess kidney function for the diagnosis and monitoring of acute kidney injury (AKI) and acute heart failure (AHF).
ParaMedir envisions a future where the obtained information is seamlessly uploaded to the hospital management system (HIS), making it accessible to relevant clinical personnel at any given time. Additionally, the integration of AI solutions holds the potential for predicting kidney function and managing AKI and AHF more effectively. The higher temporal resolution of kidney function biomarkers allows for the detection of short-term changes, leading to improved management strategies. For more information about ParaMedir and its revolutionary products, please visit www.Paramedir.nl

Source article and picture: Paramedir
Recently, the LIFE Cooperative, together with the University Medical Center Groningen (UMCG), has been working hard on submitting projects to PharmaNL.
From 2026 onwards, SpringBoard, the industry association for medical technology, will continue as part of LIFE Cooperative. This is a logical step, as both organizations pursue the same goals for their members. With this integration, the knowledge, experience, and network of SpringBoard will become part of LIFE Cooperative — the cooperative of more than 60 Northern Dutch Life Science companies. This marks an important step toward strengthening and further growing the Life Science & Health sector in the Northern Netherlands. “We complement each other perfectly and are even stronger together. By joining forces in this way, we increase the effectiveness of the solutions developed to contribute to sustainable healthcare. In doing so, we create economic opportunities for our members!” — Ronald Hesse, Director of LIFE Cooperative Joint ambition Since its founding in 2014, LIFE Cooperative has worked closely and enthusiastically with SpringBoard. On behalf of SpringBoard, Jan Thalens has played an important role in this collaboration by contributing to the further development of the cooperative as a member of LIFE Cooperative’s board. In 2025, SpringBoard decided it was time for the next step. LIFE Cooperative shares this ambition and will further expand its activities in the field of Enabling Technologies & Medical Devices starting in 2026. “Together, we are creating new opportunities for our members and strengthening the ecosystem around medical technology,” says Jan Thalens, board member of SpringBoard . About LIFE Cooperative LIFE Cooperative promotes innovation in the life sciences by facilitating collaboration between entrepreneurs, researchers, and investors. Through various programs and events, LIFE fosters the development of technologies that improve health and well-being. The cooperative represents more than 60 companies in the Northern Netherlands — from ambitious startups and innovative SMEs to international players. Together, they account for approximately 5,000 FTEs and a turnover of €500 million. About SpringBoard SpringBoard is an independent industry association for medical technology, founded in 2008 as an initiative by former employees of Cordis Roden. The network has grown to about 65 members and promotes innovation and knowledge sharing, supports entrepreneurs, and assists in setting up new companies. SpringBoard has contributed to the creation of seven new companies and around 100 jobs. Through workshops, networking events, and an open innovation platform, SpringBoard strengthens the MedTech sector and the development of human capital in the Northern Netherlands.
Peter Ketelaar, Chair of the LIFE Cooperative Board: “We are incredibly proud of Johannes and Ton. Their dedication has truly shaped the Life Sciences, Health & MedTech sector, not only in the Northern Netherlands. Their commitment, expertise, and entrepreneurship have strengthened our cooperative and had a major societal and economic impact—both nationally and internationally!” Johannes Wolters: connector and inspirer For most of his career, Johannes Wolters has been committed to advancing the Life Sciences, Health & MedTech sector in the Northern Netherlands, with a strong focus on societal and economic impact. From 2000 until his retirement earlier this year, he was the sole owner of Lode Holding—a more than 75-year-old company that flourished under his leadership. With subsidiaries Lode, ProCare, aXtion, Umaco, and Omnium, the group annually produces hundreds of medical devices and software solutions that contribute to health and rehabilitation worldwide. Almost every Olympic athlete improves their performance with equipment from Lode Holding. Johannes initiated the Wenckebach project and other large-scale collaborative initiatives, invested millions in innovative medical ideas for diverse target groups, and helped establish numerous spin-offs. His work has directly supported thousands of patients every day. Until recently, he was active in regional initiatives such as SSIG (Sport Science & Innovation Groningen), the LIFE Cooperative (as co-founder), and the Campus Trail, while also mentoring young entrepreneurs and startups. The next generation has since taken over the family business. Annelies Wolters, CEO of Lode Holding and daughter of Johannes: “My father has always dedicated himself to society and the well-being of others. Whether it’s medical innovation, supporting vulnerable groups, or inspiring young people in technology and science, his efforts have always been driven by responsibility, vision, and a deep sense of community.” Ton Vries: international innovation from Groningen For more than 35 years, Ton Vries has been a driving force in the Life Sciences & Health sector. From 2000 to 2020, he served as CEO of Syncom BV, which under his leadership grew into a successful spin-off of the University of Groningen. In 2017, he co-initiated the merger of Syncom and Mercachem, creating Symeres, a leading European contract research organization with over 600 employees worldwide. Ton is the inventor of the Dutch Resolution, a method for efficiently separating chiral compounds. This breakthrough resulted in patents, publications, licensing agreements with DSM, and four PhD theses—solidifying the Netherlands’ international leadership in pharmaceutical crystallization technology and green chemistry. He is also co-founder and CEO of BioBTX, a Groningen-based company with global impact that gives plastic waste a second life. Using its proprietary technology, residual waste streams are converted into valuable, circular building blocks for the chemical industry. The company is now preparing to build the world’s first circular aromatics plant in Delfzijl. Ton co-founded the LIFE Cooperative, guided young entrepreneurs, and realized numerous groundbreaking projects. Personally, he is known for his no-nonsense attitude, boundless energy, and popularity among colleagues. Robert Hof, former colleague at Symeres and LIFE Cooperative board member: “Ton is a true go-getter. When Syncom ran into trouble in 2008, he brought in new investors and rebuilt the company into the great success that Symeres is today. Ton is no-nonsense, not one for status or pretense. He doesn’t wear a suit—not even when Prime Minister Rutte or Queen Máxima visits. His company car? For years it was a 15-year-old Opel Astra, shared with the neighbor. With Ton, it’s always what you see is what you get . That directness and authenticity make him so beloved.” Short CV’s Career and Impact – Johannes Wolters Roles & Organizations 1985: Joined Lode as Controller 1992: Conducted a management buyout with a partner from the then-American owners of Lode 2000: Became 100% owner and CEO of Lode; shortly after, founded additional companies and Lode Holding as the parent company. Between 2000–2025, led multiple acquisitions and participated in various ventures 2023: Next generation joins the company, solidifying Lode Holding as a family business 2025: Retired on May 1, passing leadership to daughter Annelies (CEO) and son Freek (CFO) 2014–2024: Co-founder & board member of LIFE Cooperative Impact & Innovation Produced over 1,000 medical devices , benefiting millions of patients worldwide Projects spanning rehabilitation, sports, ADL equipment, prehabilitation & perioperative care Co-initiated the Campus Trail running event with Campus Groningen (since 2017) Sponsored scientific research and involved in initiatives such as Girls’ Day and student excursions Societal Engagement Mentored young entrepreneurs ( >40 start-ups/year ) Volunteer at SSIG (Sport Science & Innovation Groningen) , ~12 hours/week Advisor and board member for RVO , Smitfonds , and juror in entrepreneurship competitions Career and Impact – Ton Vries Roles & Organizations 2000–2020: CEO of Syncom BV , growing the company from 30 to over 100 employees 2017: Merged Syncom and Mercachem to create Symeres , now with over 600 employees worldwide Co-initiator of InnoLab Chemie , Cliq Swiss Tech , and BioBTX 2014–2024: Co-founder & Chair of LIFE Cooperative 2014–present: Board member of Campus Groningen Current: Board member of PharmaNL Innovation & Science PhD in Organic Chemistry, 1996, University of Groningen under Professor Hans Wijnberg Inventor of the Dutch Resolution method for separating chiral compounds Patents, publications (e.g., Angewandte Chemie ), DSM licensing, 4 PhDs supervised Impact: more efficient and sustainable pharmaceutical production, strengthening Dutch expertise in pharmaceutical crystallization technology Societal Engagement Mentor and coach to young entrepreneurs and colleagues Delivered notable projects within LIFE Cooperative Personal reputation: no-nonsense, energetic, determined, highly respected by peers Athletic: maintains daily long-distance running